Antibody–drug conjugates: in search of partners of choice
University Health Network · University of Toronto · +1 more institution
Abstract
Antibody-drug conjugates (ADCs) have become a credentialled class of anticancer drugs for both solid and hematological malignancies, with regulatory approvals mainly as single agents. Despite extensive preclinical and clinical efforts to develop rational ADC-based combinations, to date only a limited number have demonstrated survival improvements over standard of care. The most appealing partners for ADCs are those that offer additive or synergistic effects on tumor cells or their microenvironment without unacceptable overlapping toxicities. Coadministration with antiangiogenic compounds, HER2-targeting drugs, DNA-damage response agents and immune checkpoint inhibitors (ICIs) represent active forerunners.…
Citation impact
- FWCI
- 42.17
- Percentile
- 100%
- References
- 101
Authors
4- JFJesús Fuentes‐Antrás
University Health Network, University of Toronto, Princess Margaret Cancer Centre
- SGSofia Genta
University Health Network, University of Toronto, Princess Margaret Cancer Centre
- AVAbi Vijenthira
University Health Network, University of Toronto, Princess Margaret Cancer Centre
- LLLillian L. SiuCorresponding
University Health Network, University of Toronto, Princess Margaret Cancer Centre
Topics & keywords
- Drug
- Antibody-drug conjugate
- Computational biology
- Pharmacology
- Medicine
- Antibody
- Cancer research
- Monoclonal antibody
- Good health and well-being